Welcome to our dedicated page for Profusa news (Ticker: PFSA), a resource for investors and traders seeking the latest updates and insights on Profusa stock.
Profusa, Inc. (Nasdaq: PFSA) is a commercial stage digital health and medical technology company based in Berkeley, California, focused on tissue-integrated biosensors and its Lumee Oxygen tissue monitoring platform. The Profusa news feed on this page aggregates company press releases and third-party coverage related to its technology, clinical studies, commercial partnerships and capital markets activity.
Readers can expect technology and clinical news about Lumee Oxygen tissue monitoring, including study results in peripheral artery disease (PAD) and critical limb threatening ischemia (CLTI). Profusa has reported pilot phase data from a U.S.-based clinical study showing that Lumee oxygen traces strongly correlated with transcutaneous partial pressure of oxygen and that sensors remained functional for up to one year without sensor placement-related adverse events. News items also cover presentations at major vascular conferences such as Paris Vascular Insights and the Leipzig Interventional Course (LINC), where Profusa discusses additional insights into tissue oxygen monitoring.
The PFSA news stream also highlights commercial and distribution developments. Profusa has announced distributor partnerships in European markets for Lumee Oxygen tissue monitoring, including agreements intended to cover significant portions of the European Union population and to serve hospital and outpatient wound care settings. Additional releases describe collaborations with leading vascular surgeons and vascular centers in France and Greece, where Lumee technology is being adopted in clinical practice and clinical studies.
Investors will find corporate and financing updates in Profusa’s news, including details on its business combination with NorthView Acquisition Corporation, recapitalization efforts, senior secured convertible notes, and equity line of credit arrangements. The company has also outlined its own revenue targets and commercialization timelines in press releases, along with manufacturing milestones such as completion of sensor production runs and engagement of contract manufacturers for Lumee components.
By following this PFSA news page, users can track how Profusa communicates progress on its Lumee Oxygen platform, clinical validation, European commercialization plans, and balance sheet restructuring, as disclosed through its public announcements.
Profusa (Nasdaq: PFSA) entered a know-how agreement with Mayo Clinic on Feb. 12, 2026 to investigate high-impact clinical applications of its Lumee™ continuous tissue oxygen monitoring technology.
The collaboration targets potential U.S. commercialization for critical limb ischemia and new tethered products across cardiovascular, renal, multi-organ, and orthopedic indications. Profusa cites over $100 million invested in Lumee development; Mayo Clinic holds a financial interest and will use any revenue to support its mission.
Profusa (Nasdaq: PFSA) announced a 1-for-75 reverse stock split effective 12:01 am ET on February 9, 2026. Every 75 pre-split shares will consolidate into one post-split share, reducing outstanding shares from ~92.4 million to ~1.2 million.
The ticker remains PFSA and a new CUSIP 74319X207 will apply; fractional shares will be paid in cash. Authorized common shares remain 601 million.
Profusa (NASDAQ: PFSA) presented positive US pilot study results for the Lumee implantable hydrogel oxygen sensor at LINC 2026 on Jan 28, 2026.
The 15-patient study at UCSF sites showed strong correlation with tcpO2, sensors functional up to one year, no placement-related adverse events, and detected reactive hyperemia in 19% (arm) and 5% (foot) of tests. The company expects EU Lumee revenue to begin 2Q 2026 and projects 2026 revenue of $0.5–$2M and 2027 revenue of $9–$13M.
Profusa (Nasdaq: PFSA) launched the Lumee tissue oxygen Healthcare Research offering on Jan 16, 2026, making research-use-only (RUO) Lumee kits and a service-enabled platform commercially available for immediate deployment to contract research organizations (CROs).
The initiative targets the global CRO market, cited at $47.9 billion in 2025 with a projected ~7% CAGR, and is intended to generate near-term service revenue by enabling continuous, real-time tissue oxygen measurements for preclinical, translational, organ-on-chip, and other R&D applications. Profusa named Sean Givens to lead commercialization as Head of Government and Healthcare Research Business.
Profusa (Nasdaq: PFSA) announced on January 8, 2026 that Dr. Theodosios Bisdas, Head of Clinic of Vascular Surgery at Athens Medical Center, will adopt the Lumee™ Oxygen tissue monitoring platform in his clinical practice in Greece and in clinical studies for home monitoring.
The agreement covers clinical integration for inpatient and outpatient care and continued evaluations of additional vascular applications. Dr. Bisdas has led major multicenter vascular research, published over 100 scientific articles, and founded Vascupedia, a platform with over 10,000 users in 124 countries. Profusa described the collaboration as an expansion of its vascular surgeon network at the Athens Medical Center.
Profusa (NASDAQ: PFSA) announced a distribution partnership with MedSell to commercialize Lumee™ Oxygen tissue monitoring in France, expanding European coverage that now reaches roughly 200,000 CLI cases annually across the EU. The agreement complements a clinical collaboration with Pr. Yann Gouëffic, whose practices represent about 8% of CLTI cases in France. Profusa plans European commercialization beginning 2Q 2026 and targeting US commercialization in 2027, and provided revenue targets of $0.5–2M in 2026, $9–13M in 2027, and a potential goal of $200–250M by 2030.
Profusa (Nasdaq: PFSA) announced a restructuring of its Senior Secured Convertible Notes on December 30, 2025 to provide greater repayment flexibility and reduce dilution.
Key changes include an increase in the conversion floor price to $0.35 from $0.10, elimination of mandatory cash and equity amortization payments originally scheduled to begin Q1 2026, a final scheduled payment due at note maturity (18 months after issuance), and higher mandatory ELOC payments that rise from 17.5% to 33% for shares issued under the existing registration statement and to 50% for shares issued under any Form S-1 filed after this date.
Profusa (Nasdaq: PFSA) presented FDA-advised pilot phase results at Paris Vascular Insights on Dec 13, 2025 showing its Lumee™ implantable hydrogel sensors met primary end points for long-term tissue oxygen monitoring in peripheral artery disease (PAD) patients.
Key facts: 15 PAD patients were followed up to 12 months with visits on days 2, 10, 90, 180, 365; Lumee traces strongly correlated with transcutaneous partial pressure of oxygen (tcpO2); sensors remained functional up to one year; no sensor placement–related adverse events were reported. Results are said to support a potential U.S. FDA submission and a planned EU commercialization start in early 2Q 2026.
Profusa (Nasdaq: PFSA) announced that an abstract from its US pilot clinical study of the Lumee tissue oxygen monitoring technology in peripheral artery disease (PAD) patients was accepted for presentation at Leipzig Interventional Course (LINC) 2026.
The presentation is scheduled for January 28, 2026 at 9:45am CET in Trade Fair Leipzig, Hall 2, and will share additional clinical insights comparing Lumee tissue oxygen monitoring with tcpO2 from US sites. The company describes Lumee as a continuous, real-time implantable oxygen sensor intended for clinic and at-home use. Management highlighted positive feedback from the US study and plans to discuss results with providers and researchers at the conference.
Profusa (Nasdaq: PFSA) announced acceptance of a Late Breaking Clinical Trial Update presentation at Paris Vascular Insights 2025, Dec 11-13, 2025, in Paris.
The presentation, by Peter Schneider, M.D., is titled "Monitoring Tissue Oxygen Dynamics with a Novel Implantable Hydrogel Sensor in Patients with Peripheral Arterial Disease (PAD)" and is scheduled for Dec 13, 2025, 13:00–13:40 CET at Carrousel du Louvre. The update covers a U.S.-based clinical study of the Lumee oxygen tissue monitoring platform using transcutaneous partial pressure of oxygen (tcpO2) to measure continuous, real-time tissue oxygen dynamics.